Your browser doesn't support javascript.
loading
Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma.
Pignot, Géraldine; Thiery-Vuillemin, Antoine; Albigès, Laurence; Walz, Jochen; Lang, Hervé; Balssa, Loïc; Parier, Bastien; Geoffrois, Lionnel; Bensalah, Karim; Schlürmann, Friederike; Ladoire, Sylvain; Bigot, Pierre; Borchiellini, Delphine; Cassuto, Ophélie; Thibault, Constance; Ingels, Alexandre; Saldana, Véronique; Roubaud, Guilhem; Bernhard, Jean-Christophe; Gravis, Gwenaelle; Barthélémy, Philippe.
Afiliação
  • Pignot G; Department of Surgical Oncology 2, Institut Paoli-Calmettes, Marseille, France. Electronic address: pignotg@ipc.unicancer.fr.
  • Thiery-Vuillemin A; Medical Oncology Department, CHRU Besancon - Hopital Jean Minjoz, Besançon, France.
  • Albigès L; Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France.
  • Walz J; Department of Surgical Oncology 2, Institut Paoli-Calmettes, Marseille, France.
  • Lang H; Urology Department, University Hospital of Strasbourg, Strasbourg, France.
  • Balssa L; Urology Department, CHRU Besancon - Hopital Jean Minjoz, Besançon, France.
  • Parier B; Urology Department, Bicêtre Hospital, Le Kremlin Bicêtre, France.
  • Geoffrois L; Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre lès Nancy, France.
  • Bensalah K; Department of Urology, CHU Rennes - Hopital Pontchaillou, Rennes, France.
  • Schlürmann F; Department of Medical Oncology, CHRU Brest, Brest, France.
  • Ladoire S; Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.
  • Bigot P; Urology Department, CHU d'Angers, Angers, France.
  • Borchiellini D; Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.
  • Cassuto O; Department of Medical Oncology, Polyclinique St Georges, Nice, France.
  • Thibault C; Department of Medical Oncology, Hôpital Européen Georges Pompidou, Paris, France.
  • Ingels A; Urology Department, CHU Henri-Mondor, Créteil, France.
  • Saldana V; Department of Medical Oncology, CHU Henri-Mondor, Créteil, France.
  • Roubaud G; Department of Medical Oncology, Institut Bergonié, Bordeaux, France.
  • Bernhard JC; Urology Department, CHU de Bordeaux - Hôpital Pellegrin, Bordeaux, France.
  • Gravis G; Medical Oncology Department, Institut Paoli-Calmettes, Aix-Marseille Université, Inserm, CNRS, CRCM, Marseille, France.
  • Barthélémy P; Medical Oncology, Institut de Cancérologie Strasbourg Europe, Strasbourg, France.
Eur Urol Oncol ; 5(5): 577-584, 2022 10.
Article em En | MEDLINE | ID: mdl-35853818
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Neoplasias Renais Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Eur Urol Oncol Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Neoplasias Renais Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Eur Urol Oncol Ano de publicação: 2022 Tipo de documento: Article